AGN—Almost lost in the shuffle today were FDA approval of Ozurdex for DME and FDA rejection (again) of Semprana for acute migraine. AGN acquired 100% ownership of Semprana (f/k/a Levadex) in the 2013 buyout of partner, MAPP (#msg-83696395).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.